The logo of the Sanofi laboratories.

(illustration) -

Kris Tripplaar / Sipa USA / SIPA

Sanofi and GSK laboratories announced on Wednesday that they would make 200 million doses of their vaccine available to the international Covax program, launched by the WHO and whose objective is to help ensure equitable access to future vaccines against Covid-19.

They thus "intend to make available" to the program "200 million doses of their adjuvanted vaccine based on recombinant protein against Covid-19, if it is approved by the regulatory authorities and subject to the contracting ”.

The French Sanofi and the British GSK, who are jointly developing a vaccine candidate, launched a human clinical trial in September, "in which 440 participants were recruited".

They plan to obtain the first results "at the beginning of December 2020 and to be able to launch a pivotal phase III trial before the end of the year".

"If the data from these trials are sufficiently convincing to file an application for approval, a request for regulatory approval should be submitted to health authorities in the first half of 2021", specify the two groups.

A desire to make vaccines affordable

"The commitment we are making today collectively gives us better chances of controlling the pandemic," said Thomas Triomphe, executive vice-president and global manager of Sanofi Pasteur, quoted in the press release, which highlights the "will to ensure that our vaccines against Covid-19 are affordable and accessible to the most vulnerable populations, everywhere in the world ”.

“Since we began to develop vaccines against Covid-19, GSK has committed to making them available to everyone, everywhere,” said Roger Connor, president of GSK Vaccines.

In total, 167 countries have joined this international vaccine purchase and distribution mechanism: 92 low and middle-income countries that will receive doses for free, and 75 rich countries that will go through Covax to get their supplies but will have to pay for the doses of their pocket.

Health

Does the flu vaccine protect against Covid-19?

Health

AstraZeneca / Oxford vaccine induces "encouraging immune response"

  • Vaccine

  • Sanofi

  • Covid 19

  • Health

  • Coronavirus